Downregulation of FBP1 Promotes Tumor Metastasis and Indicates Poor Prognosis in Gastric Cancer via Regulating Epithelial-Mesenchymal Transition

Abstract

BackgroundRecent studies indicated that some glycolytic enzymes are complicated, multifaceted proteins rather than simple components of the glycolytic pathway. FBP1 plays a vital role in glucose metabolism, but its role in gastric cancer tumorigenesis and metastasis has not been fully understood.MethodsThe prognostic value of FBP1 was first studied in The Cancer Genome Atlas (TCGA) database and validated in in-house database. The effect of FBP1 on cell proliferation and metastasis was examined in vitro. Nonparametric test and Log-rank test were used to evaluate the clinical significance of FBP1 expression.ResultsIn the TCGA cohort, FBP1 mRNA level were shown to be predictive of overall survival in gastric cancer (P = 0.029). In the validation cohort, FBP1 expression were inversely correlated with advanced N stage (P = 0.021) and lymphovascular invasion (P = 0.011). Multivariate Cox regression analysis demonstrated that FBP1 was an independent predictor for both overall survival (P = 0.004) and disease free survival (P<0.001). Functional studies demonstrated that ectopic FBP1 expression inhibited proliferation and invasion in gastric cancer cells, while silencing FBP1 expression had opposite effects (P<0.05). Mechanically, FBP1 serves as a tumor suppressor by inhibiting epithelial-mesenchymal transition (EMT).ConclusionsDownregulation of FBP1 promotes gastric cancer metastasis by facilitating EMT and acts as a potential prognostic factor and therapeutic target in gastric cancer.

Aldolase B Overexpression is Associated with Poor Prognosis and Promotes Tumor Progression by Epithelial-Mesenchymal Transition in Colorectal Adenocarcinoma

“…The characteristics of the samples are shown in Table 1. Construction of the TMA was performed as described previously [8].…”

Gas1 Inhibits Metastatic and Metabolic Phenotypes in Colorectal Carcinoma

“…Construction of the TMA and IHC staining were performed as described previously (9,10). Gas1 and FOXM1 anti-human rabbit polyclonal antibodies were used at a dilution of 1:100 (AP11869a; Abgent) and 1:50 (sr-500; Santa Cruz Biotechnology), respectively; PBS was used alternately as negative control.…”

“…Cell proliferation was assessed by CCK8 assay as described previously (10). To determine clonogenic ability, 200 cells were transplanted in each well of a 6-well dish and allowed to grow for 14 days to form colonies.…”

“…Western blotting assay was done as described previously (10). Briefly, total proteins were isolated by lysing cells in ice-cold RIPA buffer containing protease and phosphatase inhibitors (Roche).…”

Prognostic and Clinicopathological Value of the Expression of FOXC2 &amp; YKL-40 in Carcinoma of the Breast, an Immunohistochemical Study

“…We have proved that FOXC-2 over expression was related to aggressive molecular subtype particularly triple negative breast carcinomas (TNBCs) that was in line with results of Hollier et al [13], who found that FOXC2 levels were up-regulated in triple negative breast carcinoma and also up-regulated in the to induce the expression of several cell cycle regulators, including cyclin-dependent kinase 1 (CDK1), suggesting a role for FOXC2 phosphorylation in the expression of cell cycle-specific genes and that FOXC2 may regulate the cell cycle in CSC-rich cell populations [18], that subsequently might increased proliferation in plethora of cancer types [19] [20] [21].…”